Your browser doesn't support javascript.
loading
Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy.
Rodin, Danielle; Sutradhar, Rinku; Nofech-Mozes, Sharon; Gu, Sumei; Faught, Neil; Hahn, Ezra; Fong, Cindy; Trebinjac, Sabina; Paszat, Lawrence; Rakovitch, Eileen.
Afiliação
  • Rodin D; Radiation Medicine Program, Princess Margaret Cancer Centre, 700 University Avenue, Room 7-611, Toronto, ON, M4R 1M3, Canada. danielle.rodin@rmp.uhn.ca.
  • Sutradhar R; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. danielle.rodin@rmp.uhn.ca.
  • Nofech-Mozes S; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
  • Gu S; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Faught N; Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Hahn E; Department of Pathology, University of Toronto, Toronto, ON, Canada.
  • Fong C; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
  • Trebinjac S; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.
  • Paszat L; Radiation Medicine Program, Princess Margaret Cancer Centre, 700 University Avenue, Room 7-611, Toronto, ON, M4R 1M3, Canada.
  • Rakovitch E; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Breast Cancer Res Treat ; 192(1): 223-233, 2022 Feb.
Article em En | MEDLINE | ID: mdl-35083587
ABSTRACT

PURPOSE:

The paucity of data on women with large (≥ 40 mm) DCIS tumors lead to uncertainty on the safety of breast-conserving surgery (BCS) for these patients. We evaluated the impact of large tumor size on local recurrence (LR) among women with DCIS treated with BCS ± radiotherapy (RT).

METHODS:

Treatment and outcomes were ascertained through administrative databases for all women with DCIS in Ontario from 1994 to 2003 treated with BCS ± RT with negative margins; 82% had pathology review. Cox proportional hazards model was used to evaluate the impact of tumor size on LR. 10- and 15-year LR-free survival (LRFS) were calculated using Kaplan-Meier method.

RESULTS:

The cohort includes 2049 women treated by BCS (N = 1073 with RT). Median follow-up is 14 years (IQR 9-17 years). Referenced to tumors ≤ 10 mm, the risk of LR following BCS was significantly higher for larger tumors HR ≥ 40 mm = 3.67 (95% CI 2.13, 6.33; p < 0.001), HR 26-39 mm = 2.27 (95% CI 1.47, 3.50, p < 0.001), and HR 11-25 mm = 1.42 (95% CI 1.06, 1.92, p = 0.02). However, for individuals with BCS + RT, large tumor size was not associated with a significantly increased risk of LR (HR ≥ 40 mm = 1.92 (95% CI 0.97, 3.79); HR 26-39 mm = 1.81 (95% CI 1.09-2.99)). For women with tumors ≥ 40 mm, 10-year LRFS risk for those treated by BCS alone, BCS + RT without boost, and BCS + RT with boost was 58.9%, 82.8%, and 83.9%.

CONCLUSION:

Large DCIS lesions ≥ 40 mm are associated with higher risks of LR following BCS, but high long-term LRFS rates can be achieved with the addition of breast RT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article